Drug Trial Radar · NCT02361216
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
729
Actual
Start
Apr 2015
Primary completion
Mar 2016
Study completion Mar 2017
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
Conditions
- Actinic Keratosis
Interventions
Ingenol MebutateDrug
VehicleOther
Vehicle gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Complete Resolution of Actinic Keratosis (AK)Time frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Laser & Skin Surgery Center of Indiana
Carmel, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.